A363250 Stock Overview
A biotech engineering company, specializes in molecular testing solutions to target on-site testing needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Genesystem Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩8,150.00 |
52 Week High | ₩32,000.00 |
52 Week Low | ₩5,390.00 |
Beta | 0.59 |
11 Month Change | 35.61% |
3 Month Change | 1.75% |
1 Year Change | -64.25% |
33 Year Change | -45.67% |
5 Year Change | n/a |
Change since IPO | -53.16% |
Recent News & Updates
Recent updates
Shareholder Returns
A363250 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -3.1% | 0.6% | 0.4% |
1Y | -64.3% | 15.0% | 5.2% |
Return vs Industry: A363250 underperformed the KR Biotechs industry which returned 15.4% over the past year.
Return vs Market: A363250 underperformed the KR Market which returned 6.5% over the past year.
Price Volatility
A363250 volatility | |
---|---|
A363250 Average Weekly Movement | 8.8% |
Biotechs Industry Average Movement | 7.7% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A363250's share price has been volatile over the past 3 months.
Volatility Over Time: A363250's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | n/a | www.genesystem.co.kr |
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.
Genesystem Co., Ltd. Fundamentals Summary
A363250 fundamental statistics | |
---|---|
Market cap | ₩56.93b |
Earnings (TTM) | -₩11.27b |
Revenue (TTM) | ₩1.57b |
36.3x
P/S Ratio-5.1x
P/E RatioIs A363250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A363250 income statement (TTM) | |
---|---|
Revenue | ₩1.57b |
Cost of Revenue | ₩2.47b |
Gross Profit | -₩904.72m |
Other Expenses | ₩10.36b |
Earnings | -₩11.27b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.61k |
Gross Margin | -57.76% |
Net Profit Margin | -719.17% |
Debt/Equity Ratio | 13.7% |
How did A363250 perform over the long term?
See historical performance and comparison